mental health research: options for depression

Acapella study – a new treatment for depression

The Acapella study is evaluating a new drug designed to work alone or in combination with an antidepressant, to see if it can help to improve symptoms of moderate to severe major depression in healthy adults.

Study Details

The Acapella study will randomly assign participants to either the study drug or a placebo during the study intervention period. The trial consists of:

  • A screening period (up to 28 days)
  • A study intervention (study drug or placebo) period (28 days)
  • A follow-up period (14 days)
  • A total of eight on site visits and 2 telehealth visits

How Do I Qualify?

You may be eligible if*:

  • You are currently experiencing a depressive episode and:
    • You are on a stable dose of antidepressant therapy with no significant improvement in your symptoms
  • You are currently experiencing a depressive episode and:
    • You are not currently taking antidepressant therapy
  • You are between the ages of 18-65.

*Other eligibility criteria apply

What is a Research Study?

A research study may show that the study drug is better than, as good as, or worse than the standard treatment or inactive placebo (looks like the study drug but contains no active ingredient). Qualified doctors, nurses, and other medical professionals are responsible for conducting the study.

It is only through the completion of research studies that study drugs can be evaluated and, if proven safe and effective, approved for a particular use. Different regulatory bodies in different countries will provide this approval after a thorough review. Prescription medications in use today were first proven safe and effective during research studies.

© 2022 NeuroCentrix | Privacy Statement | Terms & Conditions